{"product_id":"henrui-ansoff-matrix","title":"Jiangsu Hengrui Medicine Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Amsoff Matrix Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Jiangsu Hengrui Medicine Amsoff Matrix Analysis gives a clear, structured view of the company’s growth options across market penetration, market development, product development, and diversification. The page already shows a real preview of the actual analysis, so you can see the content and format before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNRDL-backed oncology defense\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. defends oncology share by keeping core brands on China’s NRDL and hospital formularies, which lowers patient out-of-pocket costs and supports prescribing. Camrelizumab now covers 10-plus approved indications in 2025, so one hospital can use it across multiple cancers and lines of therapy. That matters in China, where penetration usually rises by treating more patients and more tumor types, not by pushing price.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTender discipline in mature products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. uses mature brands and scale manufacturing to protect access in volume-based procurement and provincial tenders, even when prices fall. In China, centralized procurement has often cut prices by 50% to 90%, so one tender round can quickly reset demand. The trade-off is clear: accept lower unit prices on older assets to keep high-volume channels and factory load high. This is classic market penetration, where share is defended by price discipline, not price power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic-area concentration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. concentrates its field force on oncology, cardiovascular, metabolic disease, and immunology, so sales teams can call on the same specialists more often and build deeper key-account coverage. That focus makes each new indication cheaper to launch because doctors already know the brand and its evidence base. In 2025, this kind of therapeutic clustering supports faster uptake and better use of commercial spend versus a broad, thin rollout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIndication stacking on existing assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. uses indication stacking to expand one molecule into several approved uses, so it can reuse clinical data and sales channels. A second or third indication can raise revenue without building a new launch platform, which cuts time and cost. In China, that works well once doctors trust the brand and local evidence, so access can improve faster than with a first-in-class launch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina field execution and patient support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. uses hospital education, KOL advocacy, and patient-support programs in China to turn launch awareness into repeat prescribing. This works best on defended brands, where field teams can protect share and convert clinician interest into patient starts over a 12-month cycle. The approach matters most in crowded hospital channels, where sustained access and adherence drive revenue more than one-time launch spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHengrui Expands Camrelizumab Reach as Access, Not Price, Drives Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. drives market penetration by widening camrelizumab to 10+ approved indications in 2025 and keeping core brands on NRDL and hospital formularies. Volume-based procurement can cut prices 50% to 90%, so share gains come from access, not margin. Focused sales teams and indication stacking let one brand reach more patients fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 factor\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCamrelizumab indications\u003c\/td\u003e\n\u003ctd\u003e10+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement price cuts\u003c\/td\u003e\n\u003ctd\u003e50% to 90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nOutlines Jiangsu Hengrui Medicine’s growth options across existing and new products and markets\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nHelps Jiangsu Hengrui Medicine quickly map pain-point relief opportunities across existing and new products and markets with a clear Ansoff Matrix view.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEx-China licensing expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. is using ex-China licensing to push China-origin assets into the US, Europe, and other markets without first funding a full 3-continent sales force. One clear sign is its out-licensing model, including deals with upfront cash and milestones such as USD 200 million upfront and up to USD 1.9 billion in potential payments on selected assets. This lowers launch risk, keeps capex light, and lets Jiangsu Hengrui Medicine Co., Ltd. test global demand with existing molecules before building its own overseas commercial team.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartner-led regional launch model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. uses partner-led regional launches to tap local regulatory, reimbursement, and distribution systems instead of building every market alone. That can cut the approval-to-sales lag by 12 to 24 months, which matters when speed to market beats immediate global scale. In 2025, this fit a model where faster regional coverage can raise launch efficiency without the cost and delay of full in-house rollout. It is a practical Market Development move in Ansoff terms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal clinical registration strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. uses multinational clinical studies to back approvals outside China, often by running work in 2 or 3 regions at once. That can lift the odds that a late-stage asset reaches global markets and supports stronger license-out talks. In 2025, this kind of multi-region package is key because it cuts duplicate trial work and gives buyers cleaner evidence for filing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging-market entry with existing assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. can push approved or near-approved oncology and hospital drugs into Southeast Asia, Latin America, and the Middle East through local partners. These regions cover more than 1.3 billion people and still want branded specialty medicines, but they do not need the sales force or supply scale of the US. That makes them a low-capex bridge for international growth in 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse partners to cut launch risk.\u003c\/li\u003e\n\u003cli\u003eStart with oncology and hospital brands.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-core country-by-country expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. can push non-core, country-by-country expansion by picking the 2 or 3 best-fit markets for each molecule, rather than forcing China-only launch. That speeds monetization and spreads regulatory, pricing, and reimbursement risk across markets, which matters most for innovative drugs aimed at narrow patient groups. In 2025, this selective rollout model can also protect capital by avoiding broad launch costs in weak-fit countries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHengrui’s China-to-Global Deal Model Fuels Fast, Low-Capex Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Jiangsu Hengrui Medicine Co., Ltd. used market development to sell China-made assets through ex-China partners, avoiding a full overseas sales buildout. Deals like USD 200 million upfront plus up to USD 1.9 billion in milestones show how it expands into the US, Europe, and other regions with low capex and faster launch access. This approach fits oncology and specialty drugs best.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront cash\u003c\/td\u003e\n\u003ctd\u003eUSD 200m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential milestones\u003c\/td\u003e\n\u003ctd\u003eUSD 1.9bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eJiangsu Hengrui Medicine Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Jiangsu Hengrui Medicine Amsoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003cp\u003eThe preview below is taken directly from the full Amsoff Matrix report you'll get. Purchase unlocks the complete in-depth version.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing a live preview of the actual analysis file. The full Jiangsu Hengrui Medicine Amsoff Matrix document becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e90-plus clinical pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd.’s 90-plus clinical programs give it the scale to keep 3 to 5 launch candidates moving at once across different stages. That lowers the risk of relying on one blockbuster and supports steady product development under Ansoff Matrix product development logic. With more than 90 trials in play, Jiangsu Hengrui Medicine Co., Ltd. can spread R\u0026amp;D bets and build a deeper near-term launch funnel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigher-value oncology modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn 2025, Jiangsu Hengrui Medicine Co., Ltd. kept pushing higher-value oncology modalities, especially ADCs and bispecific antibodies, to build on its cancer base. These formats can beat older small molecules in 1 to 2 key settings if they deliver clearer efficacy or safety gains. That fit is strong because Jiangsu Hengrui Medicine Co., Ltd. already has oncology sales channels, trial know-how, and physician ties, which can speed uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMetabolic and immunology follow-ons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine is moving beyond oncology into metabolic disease and immunology, where chronic use can build durable franchises. These follow-ons are platform bets, not one-off launches, and the same mechanism can support several indications over 5-plus years. That gives Jiangsu Hengrui Medicine a longer product runway and a better chance to spread R\u0026amp;D risk across multiple revenue pools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLine extensions from approved brands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. uses line extensions from approved brands by adding new indications, new combinations, and new formulations. This is usually cheaper than creating a new molecule because it can reuse much of the clinical, regulatory, and commercial base. It also speeds revenue conversion since the sales team and physician reach are already in place.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D intensity above 20%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. keeps R\u0026amp;D intensity above 20% of revenue, which is a heavy but necessary bet for a pipeline-led model. In drugs, Phase 2 to launch often takes 4 to 8 years, so 2025 profit takes the hit while the 2026-2028 launch queue gets deeper.\u003c\/p\u003e\n\u003cp\u003eThat spend should support more late-stage readouts, but it also keeps near-term margins under pressure. For an Amsoff Product Development strategy, the signal is clear: more internal innovation today, more launch optionality later.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHengrui’s 2025 R\u0026amp;D Push Sets Up a Deeper 2026-28 Launch Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Jiangsu Hengrui Medicine Co., Ltd. kept product development broad, with 90-plus clinical programs and more than 90 trials supporting 3 to 5 launch candidates at once. Its focus stayed on higher-value oncology assets, especially ADCs and bispecific antibodies, while also moving into metabolic disease and immunology. R\u0026amp;D intensity stayed above 20% of revenue, so near-term profit stayed tight but the 2026-2028 launch pipeline got deeper.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical programs\u003c\/td\u003e\n\u003ctd\u003e90+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrials in play\u003c\/td\u003e\n\u003ctd\u003e90+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch candidates\u003c\/td\u003e\n\u003ctd\u003e3-5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D intensity\u003c\/td\u003e\n\u003ctd\u003e20%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-modality innovation mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. is widening its mix beyond one chemistry base, with 3 visible bets in 2025: ADCs, bispecific antibodies, and peptide assets. Each modality can serve different patient groups and price points, so the pipeline is less tied to one drug class or one market outcome. That spread should broaden revenue sources and reduce dependence on any single therapeutic platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEx-China deal economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. is using ex-China licensing to diversify beyond China sales. One global deal can create 2 revenue streams: domestic product sales plus overseas upfront fees, milestones, and royalties, which can fund R\u0026amp;D in 2025-2026 without leaning only on home-market demand. That lowers concentration risk and makes cash flow less tied to one geography.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdjacency into chronic disease franchises\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. is moving into metabolic and immunology adjacencies, which are structurally different from acute hospital oncology sales. These chronic-disease franchises can create recurring demand for 12 months or longer, so revenue should be steadier than one-off hospital orders.\u003c\/p\u003e\n\u003cp\u003eThis also widens Jiangsu Hengrui Medicine Co., Ltd.’s addressable market beyond hospital-only purchasing, with more room in outpatient and long-term treatment channels.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-licensing and selective external assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. can diversify by in-licensing differentiated assets when internal discovery is slower, adding 1 or 2 ready-made programs and cutting time to market. In 2025, that matters because late-stage drug development still takes years and carries high failure risk, so external assets can widen the pipeline with less scientific rebuild. It is a practical way to expand beyond the core and avoid building every platform in-house.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina plus global portfolio balance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJiangsu Hengrui Medicine Co., Ltd. is building one portfolio for China reimbursement and another for global partner monetization, so it is not tied to one market’s rules. That mix helps offset China price pressure with overseas milestone and royalty income, while reducing dependence on any single approval cycle. In 2025, that split is still the cleanest way for Jiangsu Hengrui Medicine Co., Ltd. to spread risk across markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHengrui’s 2025 pivot: three modalities, two revenue streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2025, Jiangsu Hengrui Medicine Co., Ltd. is diversifying across 3 drug modalities: ADCs, bispecific antibodies, and peptides. It is also using ex-China deals to create 2 income streams: home sales plus upfronts, milestones, and royalties. That cuts reliance on one product, one therapy area, or one market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025 diversification lever\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eRisk reduced\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eModality mix\u003c\/td\u003e\n\u003ctd\u003e3 bets\u003c\/td\u003e\n\u003ctd\u003ePlatform concentration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal licensing\u003c\/td\u003e\n\u003ctd\u003e2 revenue streams\u003c\/td\u003e\n\u003ctd\u003eChina-only dependence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew adjacencies\u003c\/td\u003e\n\u003ctd\u003e12 months+ demand\u003c\/td\u003e\n\u003ctd\u003eHospital-order volatility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Balanced Scorecard","offers":[{"title":"Default Title","offer_id":53646767948118,"sku":"henrui-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1027\/3715\/0294\/files\/henrui-ansoff-analysis.webp?v=1778886513","url":"https:\/\/balancedscorecardexamples.com\/products\/henrui-ansoff-matrix","provider":"Balanced Scorecard","version":"1.0","type":"link"}